EMEA-001638-PIP02-21
Key facts
| Invented name |
Tecentriq
|
| Active substance |
atezolizumab
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0384/2021
|
| PIP number |
EMEA-001638-PIP02-21
|
| Pharmaceutical form(s) |
Solution for injection
|
| Condition(s) / indication(s) |
Treatment of all conditions included in the category of malignant neoplasms (except central nervous system tumours, hematopoietic and lymphoid tissue neoplasms and melanoma)
|
| Route(s) of administration |
Subcutaneous use
|
| Contact for public enquiries |
Roche Registration GmbH
E-mail: global.paediatrics@roche.com |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|